AbbVie's Leukemia Drug Falls Short In Late-Stage Study In Pretreated Blood Cancer Patients - AbbVie (NYSE:ABBV)

Data did not demonstrate that the treatment combination significantly improved progression-free survival (PFS), the trial's primary endpoint.

Patients receiving VenDex showed improvement in median PFS of 9.9 months compared to 5.8 months with the combination of study comparator pomalidomide and dexamethasone (PomDex); however, the results did not reach statistical significance.

Select prespecified secondary endpoints include:

Overall response rate (ORR): 62% in VenDex vs. 35% in PomDex.
Rate of very good partial response or better (VGPR) at 39% in VenDex vs. 14% in PomDex.
Median overall survival (OS) was 32.4 months in VenDex vs. 24.5 months in PomDex.

Additional prespecified analyses include:

Price Action: ABBV shares are down 1.81% at $149.50 on the last check Friday.

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.

AbbVie Inc (NASDAQ:ABBV) released data from its Phase 3 CANOVA study evaluating venetoclax (Venclexta/ Venclyxto) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received two or more prior treatments.

Data did not demonstrate that the treatment combination significantly improved progression-free survival (PFS), the trial's primary endpoint.

Select prespecified secondary endpoints include:

Overall response rate (ORR): 62% in VenDex vs. 35% in PomDex.
Rate of very good partial response or better (VGPR) at 39% in VenDex vs. 14% in PomDex.
Median overall survival (OS) was 32.4 months in VenDex vs. 24.5 months in PomDex.

Additional prespecified analyses include:

PFS per investigator resulted in a median PFS of 9.1 months with VenDex vs. 4.9 months with PomDex.
Median time to next treatment (TTNT), which was longer in the VenDex arm, 21.2 months vs. 8.3 months in the PomDex arm
Multiple myeloma is the second most common blood cancer in the world.
Venetoclax is approved for patients with previously untreated and treated chronic lymphocytic leukemia (CLL) and newly diagnosed acute myeloid leukemia (AML).

Price Action: ABBV shares are down 1.81% at $149.50 on the last check Friday.

ABBVAbbVie Inc

$227.25-0.11%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.